Christophe Chardot

Dr. Christophe Chardot

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
MFMartina Fanna
Martina Fanna
GMGuillaume Masson
Guillaume Masson
CCCarmen Capito
Carmen Capito
MGMuriel Girard
Muriel Girard
FGFlorent Guerin
Florent Guerin
CCChristophe Chardot
Christophe Chardot

15 March 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
TLThuy-Linh Le
Thuy-Linh Le
LGLouise Galmiche
Louise Galmiche
JLJonathan Levy
Jonathan Levy
PSPim Suwannarat
Pim Suwannarat
DHDebby M.E.I. Hellebrekers
Debby M.E.I. Hellebrekers
NBNadege Bondurand
Nadege Bondurand
Hirschsprung disease (HSCR) is the most frequent developmental anomaly of the enteric nervous system, with an incidence of 1 in 5000 live births. Chronic intestinal pseudo-obstruction (CIPO) is less frequent and classified as neurogenic or myogenic. Isolated HSCR has an oligogenic inheritance with RET as the major disease-causing gene, while CIPO is genetically heterogeneous, caused by mutations in smooth muscle–specific genes. Here, we describe a series of patients with developmental disorders including gastrointestinal dysmotility, and investigate the underlying molecular bases. Trio-exome sequencing led to the identification of biallelic variants in ERBB3 and ERBB2 in 8 individuals variably associating HSCR, CIPO, peripheral neuropathy, and arthrogryposis. Thorough gut histology revealed aganglionosis, hypoganglionosis, and intestinal smooth muscle abnormalities. The cell type–specific ErbB3 and ErbB2 function was further analyzed in mouse single-cell RNA sequencing data and in a conditional ErbB3-deficient mouse model, revealing a primary role for ERBB3 in enteric progenitors. The consequences of the identified variants were evaluated using quantitative real-time PCR (RT-qPCR) on patient-derived fibroblasts or immunoblot assays on Neuro-2a cells overexpressing WT or mutant proteins, revealing either decreased expression or altered phosphorylation of the mutant receptors. Our results demonstrate that dysregulation of ERBB3 or ERBB2 leads to a broad spectrum of developmental anomalies, including intestinal dysmotility.

29 July 2021 in Children
Verified
Journal Article
Open access
PDF file
ABAlastair Baker
Alastair Baker
EFEsteban Frauca
Esteban Frauca
JTJuan Torres
Juan Torres
LBLuz Yadira Bravo-Gallego
Luz Yadira Bravo-Gallego
EFEmer Fitzpatrick
Emer Fitzpatrick
PVPaloma Jara Vega
Paloma Jara Vega
(1) Background: Post-transplant lymphoproliferative disease (PTLD) is a significant complication of solid organ transplantation (SOT). However, there is lack of consensus in PTLD management. Our aim was to establish a present benchmark for comparison between international centers and between various organ transplant systems and modalities; (2) Methods: A cross-sectional questionnaire of relevant PTLD practices in pediatric transplantation was sent to multidisciplinary teams from 17 European center members of ERN TransplantChild to evaluate the centers’ approach strategies for diagnosis and treatment and how current practices impact a cross-sectional series of PTLD cases; (3) Results: A total of 34 SOT programs from 13 European centers participated. The decision to start preemptive treatment and its guidance was based on both EBV viremia monitoring plus additional laboratory methods and clinical assessment (61%). Among treatment modalities the most common initial practice at diagnosis was to reduce the immunosuppression (61%). A total of 126 PTLD cases were reported during the period 2012–2016. According to their histopathological classification, monomorphic lesions were the most frequent (46%). Graft rejection after PTLD remission was 33%. Of the total cases diagnosed with PTLD, 88% survived; (4) Conclusions: There is still no consensus on prevention and treatment of PTLD, which implies the need to generate evidence. This might successively allow the development of clinical guidelines.

1 August 2021 in Clinical Nutrition
Verified
Journal Article
Closed access
FPFrancesco Proli
Francesco Proli
AFAndrea Faragalli
Andrea Faragalli
CTCécile Talbotec
Cécile Talbotec
ABAndrea Bucci
Andrea Bucci
Boutaina ZemraniBoutaina Zemrani
Boutaina Zemrani
CLCécile Lambe
Cécile Lambe

1 October 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
SCSophie Courbage
Sophie Courbage
DCDanielle Canioni
Danielle Canioni
CTCécile Talbotec
Cécile Talbotec
CLCécile Lambe
Cécile Lambe
CCChristophe Chardot
Christophe Chardot
FLFlorence Lacaille
Florence Lacaille
Long-term outcomes in children undergoing intestinal transplantation remain unclear. Seventy-one children underwent intestinal transplantation in our center from 1989 to 2007. We report on 10-year posttransplant outcomes with (group 1, n = 26) and without (group 2, n = 9) a functional graft. Ten-year patient and graft survival rates were 53% and 36%, respectively. Most patients were studying or working, one third having psychiatric disorders. All patients in group 1 were weaned off parenteral nutrition with mostly normal physical growth and subnormal energy absorption. Graft histology from 15 late biopsies showed minimal abnormality. However, micronutrient deficiencies and fat malabsorption were frequent; biliary complications occurred in 4 patients among the 17 who underwent liver transplantation; median renal clearance was 87 mL/min/1.73 m2 . Four patients in group 1 experienced late acute rejection. Among the 9 patients in group 2, 4 died after 10 years and 2 developed significant liver fibrosis. Liver transplantation and the use of a 3-drug regimen including sirolimus or mycophenolate mofetil were associated with improved graft survival. Therefore, intestinal transplantation may enable a satisfactory digestive function in the long term. The prognosis of graft removal without retransplantation is better than expected. Regular monitoring of micronutrients, early psychological assessment, and use of sirolimus are recommended.

7 November 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MDMark Davenport
Mark Davenport
OMOmid Madadi-Sanjani
Omid Madadi-Sanjani
CCChristophe Chardot
Christophe Chardot
HVHenkjan J Verkade
Henkjan J Verkade
SKSaul Karpen
Saul Karpen
CPClaus Petersen
Claus Petersen
Biliary atresia, a fibro-obliterative disease of the newborn, is usually initially treated by Kasai portoenterostomy, although there are many variations in technique and different options for post-operative adjuvant medical therapy. A questionnaire on such topics (e.g., open vs. laparoscopic; the need for liver mobilisation; use of post-operative steroids; use of post-operative anti-viral therapy, etc.) was circulated to delegates (n = 43) of an international webinar (Biliary Atresia and Related Diseases—BARD) held in June 2021. Respondents were mostly European, but included some from North America, and represented 18 different countries overall. The results of this survey are presented here, together with a commentary and review from an expert panel convened for the meeting on current trends in practice.